"name","id","label","rationale","uuid:ID","description"
"Study Design 1","StudyDesign_1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","c8187c6b-21d3-457a-a011-1b8cdce12de8","The main design for the study"
